Thorsten Braun, MD, PhD, Hôpitaux de Paris, Université Paris 13, Bobigny, France, outlines the current landscape and future directions in treating patients with acute myeloid leukemia (AML). Dr Braun discusses targeted therapies, liposomal daunorubicin/cytarabine and venetoclax-based therapies. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).